1. Scrip
  2. >>New Products

Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections

 
• By Joseph Haas

Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.

Hospital building
Melinta will focus on hospitals when it launches antifungal Rezzayo • Source: Shutterstock

Cidara Therapeutics, Inc. and its US commercialization partner Melinta Therapeutics, Inc. plan a mid-summer launch of Rezzayo (rezafungin), a next-generation injectable antifungal approved by the US Food and Drug Administration on 22 March, with Melinta planning a focus on physician education around drug-resistant fungal infections.

“We are timing the launch of Rezzayo with commercial supply availability and continue to work closely with our manufacturing partners to secure product for summer 2023,” Melinta CEO Christine Miller told Scrip

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.